Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO Update: Returns Sag As Seven More Biopharmas Go Public In September

Executive Summary

The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.

Advertisement

Related Content

Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Finance Watch: Three New Funds, Including Former Amgen R&D Head Harper's Next Venture
Finance Watch: Lots Of Money, Big And Small, Flowing Into Drug Development
Deal Watch: Allogene Gets Pfizer's Off-The-Shelf CAR-T Program, $300m Series A Backing
Alzheon IPO To Fund New Phase III Trialling Of Failed Alzheimer's Drug
Finance Watch: Cash Flows Into Public Biopharmas, Including IPOs; Atlas Raises $350m VC Fund
Arix Pegs LogicBio's Technology As 'Occam's Razor' Of Gene Therapy
Deal Watch: Sanofi Begins 2017 By Ending Vaccine JV, Completing Swap With Boehringer
VC Round-Up: Microbiome Focused Lodo, T-Cell Firm Tmunity, And More
AZ Spins Out Entasis To Tackle Resistant Infections

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel